Financials LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Healthcare Facilities & Services

Market Closed - Nasdaq 01:30:00 01/06/2024 am IST 5-day change 1st Jan Change
5.57 USD -.--% Intraday chart for LifeStance Health Group, Inc. -2.28% -28.86%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 3,562 1,857 2,964 2,129 - -
Enterprise Value (EV) 1 3,585 1,974 3,166 2,266 2,253 2,161
P/E ratio -9.07 x -8.1 x -15.4 x -23.1 x -25.8 x -40.4 x
Yield - - - - - -
Capitalization / Revenue 5.34 x 2.16 x 2.81 x 1.75 x 1.55 x 1.37 x
EV / Revenue 5.37 x 2.3 x 3 x 1.86 x 1.64 x 1.39 x
EV / EBITDA 72.9 x 37.5 x 53.6 x 25.3 x 18.5 x 13.6 x
EV / FCF -42.1 x -74.6 x -55.2 x 214 x 57.8 x 37.9 x
FCF Yield -2.37% -1.34% -1.81% 0.47% 1.73% 2.64%
Price to Book 2.31 x 1.22 x 2.08 x 1.53 x 1.54 x 1.54 x
Nbr of stocks (in thousands) 3,74,149 3,75,986 3,78,607 3,82,288 - -
Reference price 2 9.520 4.940 7.830 5.570 5.570 5.570
Announcement Date 10/03/22 08/03/23 28/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 377.2 667.5 859.5 1,056 1,218 1,377 1,557
EBITDA 1 - 49.15 52.67 59.04 89.65 122 159.4
EBIT 1 - -286.4 -210.2 -189.1 -79.1 -66.9 -36.9
Operating Margin - -42.9% -24.45% -17.92% -6.5% -4.86% -2.37%
Earnings before Tax (EBT) 1 - -333.1 -232.7 -206.6 -102.3 -85.71 -61.04
Net income 1 -311.3 -343.9 -215.6 -186.3 -89.93 -76.33 -48.03
Net margin -82.53% -51.53% -25.08% -17.64% -7.39% -5.54% -3.09%
EPS 2 - -1.050 -0.6100 -0.5100 -0.2407 -0.2157 -0.1379
Free Cash Flow 1 - -85.07 -26.47 -57.4 10.57 39 57
FCF margin - -12.74% -3.08% -5.44% 0.87% 2.83% 3.66%
FCF Conversion (EBITDA) - - - - 11.8% 31.95% 35.76%
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 12/04/21 10/03/22 08/03/23 28/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 190.1 203.1 209.5 217.6 229.4 252.6 259.6 262.9 280.6 300.4 306 301.7 312.4 330 336.4
EBITDA 1 11.4 12.48 14.63 15.38 10.18 10.1 14.06 14.58 20.29 27.65 22.38 21.65 23.11 26.58 29.49
EBIT 1 -113.8 -64.85 -60.47 -38.84 -46.01 -34.09 -48.41 -74.36 -32.27 -16.77 -27.4 -26.4 -23.9 - -
Operating Margin -59.84% -31.93% -28.86% -17.85% -20.06% -13.5% -18.65% -28.28% -11.5% -5.58% -8.95% -8.75% -7.65% - -
Earnings before Tax (EBT) 1 -118.6 -69 -67.8 -42.21 -53.72 -38.28 -52.02 -77.97 -38.32 -20.73 -30 -30 -28 - -
Net income 1 -144.8 -62.33 -68.73 -37.85 -46.66 -34.24 -45.48 -61.58 -44.96 -21.1 -29.15 -28.2 -25.85 - -
Net margin -76.16% -30.69% -32.8% -17.4% -20.34% -13.56% -17.52% -23.42% -16.02% -7.02% -9.53% -9.35% -8.28% - -
EPS 2 -0.3200 -0.1800 -0.1900 -0.1100 -0.1300 -0.0900 -0.1300 -0.1700 -0.1200 -0.0600 -0.0614 -0.0656 -0.0640 -0.0550 -0.0468
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/03/22 09/05/22 09/08/22 08/11/22 08/03/23 10/05/23 09/08/23 08/11/23 28/02/24 09/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 23.5 116 201 137 124 31.3
Net Cash position 1 - - - - - - -
Leverage (Debt/EBITDA) - 0.4783 x 2.211 x 3.412 x 1.526 x 1.014 x 0.1963 x
Free Cash Flow 1 - -85.1 -26.5 -57.4 10.6 39 57
ROE (net income / shareholders' equity) - -27.1% -14.1% -12.6% -6.48% -5.03% -3.32%
ROA (Net income/ Total Assets) - -19.7% -10.5% -8.7% -5.07% -3.9% -3.18%
Assets 1 - 1,748 2,050 2,142 1,773 1,960 1,511
Book Value Per Share 2 - 4.130 4.040 3.770 3.650 3.620 3.630
Cash Flow per Share 2 - 0.0300 0.1500 -0.0500 0.1100 0.2400 -
Capex 1 - 94.5 79.3 40.5 32.6 57.3 68.7
Capex / Sales - 14.16% 9.22% 3.84% 2.67% 4.16% 4.41%
Announcement Date 12/04/21 10/03/22 08/03/23 28/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
5.57 USD
Average target price
8.786 USD
Spread / Average Target
+57.73%
Consensus
  1. Stock Market
  2. Equities
  3. LFST Stock
  4. Financials LifeStance Health Group, Inc.